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Abstract: Vascular dilatation is critically impaired in many diseases and is encountered by 
an upregulated endothelin receptor A (ETA) in the vasculature in association with a decline in 
nitric oxide bioavailability. Diabetic vasculopathy is characterized as a compromised vascular 
  dilatation, implicated in many diabetic complications. It appears to be activated ETA and NADPH 
(  nicotinamide adenine dinucleotide phosphate) oxidase in the vasculature. Glucose-lowering 
agents do not always blunt these changes, as these changes may be progressive leading to the end 
stage of renal disease. The vascular insults by hypertension, hyperglycemia and aging may share 
the changes with diabetic vascular beds. Endothelin receptor antagonist CPU0213 and ingredients 
from plant origins such as CPU86017, p-benzyl-tetra-hydro-berberine are effective in attenuating 
vascular abnormality by normalizing changes of biomarkers in the   vascular wall. The early sign 
of subclinical atherosclerosis presented as an intima media thickness in the carotid may indicate 
endothelium dysfunction. The reduced ABI (ankle brachial index) has been taken to predict 
patients at risk for cardiovascular and cerebrovascular events, and an increased risk of mortality 
from all causes and cardiovascular disease. An application of agents which   suppress the activated 
ET-NADPH oxidase in the vascular wall is beneficial to attenuate vascular   abnormalities. It is 
worth testing the activity of these agents further for the potential in relieving abnormal vascular 
activity, reducing the risk of morbidity and mortality in patients at risk.
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Introduction
Normal vascular activity is essential for maintaining normal function of organs, 
  dependent on a balance of vasoconstrictive and vasodilative substances derived from the 
vascular endothelium, which mainly include nitric oxide (NO) to dilate and endothelin-1 
to constrict the vascular smooth muscle. Endothelium-dependent relaxation directly 
relates to the biosynthesis and release of NO by the activity of endothelial nitric oxide 
synthase (eNOS) in the endothelium. Vascular relaxation is encountered by an activated 
endothelin (ET-1) system, and an over-activated ETA (endothelin receptor A) may con-
tribute to a decline in eNOS activity, resulting in compromised NO bioavailability.1
Endothelial dysfunction characterized by impaired endothelium-dependent 
  vasodilatation has been linked to each of the known risk conditions, such as diabetes 
  mellitus, hypertension, dyslipidemia, obesity, cigarette smoking, and aging. The more 
impaired vascular endothelium, the more severe the risk for cardiovascular events such 
as coronary infarction; thus, it is likely to take an impaired vascular endothelium as 
the early stage of coronary infarction.2
Regarding the high incidence of morbidity and   mortality of cardiovascular 
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Dovepress 
Dovepress
788
Dai and Dai
more   understanding of the mechanisms in pathologies of 
  complications of diabetes, hyperlipidemia, and stress-related 
abnormalities.
ET-1 is primarily active as paracrine substance that 
  modulates the basal vascular tone. ETA appears to be at the 
center in modulating the vascular activity, and an upregulated 
ETA has been found under multiple conditions:   congestive 
heart failure, hypertension, atherosclerosis,   endothelial 
  dysfunction, coronary artery diseases, renal failure, 
  cerebrovascular disease, pulmonary arterial hypertension, 
and sepsis.3 Interestingly, some substances and   prescriptions 
in Traditional Chinese Medicine (TCM) may be effective in 
reversing endothelial insults by suppressing the activated 
ETA, such as quercetin, isorhamnetin, or chelerythrine 
(protein kinase C (PKC) inhibitor), a modified rehmannia 
decoction (Liu-wei-di-huang decoction), and total triterpene 
acids isolated from corni fructus.1,4,5
CPU86017 (Figure 1A), a derivative from berberine, 
has been found to be effective in suppressing potassium and 
  calcium channels.6,7 It relieves the abnormalities of pulmonary 
artery hypertension, the abnormalities of   calcium modulating 
proteins in a failing heart, and diabetic cardiomyopathy.8–11 
There are 2 chiral centers at 7N and 13Cα (Figure 1B); 
  consequently, 4 enantiomers that are derived from chiral 
separation share beneficial effects on the pulmonary hyper-
tension through suppressing the ET receptor.12 Besides, a new 
endothelin receptor antagonist, CPU0213 (Figure 1C), which 
suppresses both the ETA and ETB, referred as a   nonselective 
(or dual) endothelin receptor antagonist which is effective in 
suppressing upregulated ET receptors resulting in relieving 
pulmonary arterial hypertension and vascular abnormalities 
in diabetic vasculature.1,13
Vascular abnormalities  
and oxidative stress
Vascular activity depends on a normal endothelium, 
which releasing vasoactive substances to regulate vascular 
smooth muscle tone. The ability of formation and release 
of   vascular dilating substance NO in the endothelium is 
seriously affected by oxidative stress, which appears to 
reduce the vascular dilatation in response to acetylcholine 
(ACh) due to less vascular NO released. Hyperglycemia 
induces advanced glycation end products (AGEs), which 
have the entity of free radicals affecting the large biological 
molecules to injure cells. Compromised vascular dilatation 
by diabetic lesion results from an excess of ROS (reactive 
oxygen species), which is evidenced that ROS are released 
from cardiomyocyte while incubated with high glucose.14 
It has been widely accepted that ROS induced by hyper-
glycemia contribute to vascular endothelium dysfunction 
in diabetes.15 A variety of   enzymatic and non-enzymatic 
sources of ROS exist in the blood vessels, including 
NADPH oxidase (NOX), mitochondrial electron transport 
chain, xanthine oxidase, and nitric oxide synthase. Among 
them the   dysfunction of   mitochondrial electron transport 
and activated NOX are critically important in generating 
oxidative stress causing maladaptive vascular responses. 
Accumulated evidence indicates that in diabetic rats, 
  upregulated NOX has been found in the thoracic vascular 
ring of which the vascular relaxation decreases signifi-
cantly along with an augmented vascular tone developed 
in response to phenylephrine.16 NOX is composed by 2 
groups of subunit portions: the catalytic components Nox1, 
Nox4, gp91 phox; and the   modulating components p22phox, 
p47phox, p67phox, which localize either at the membrane or 
in the cytosol.17 The   production of ROS can be augmented 
while an activation of the enzyme is taking place by moving 
the cytosolic elements to the membrane, allowing the passage 
of electron from oxygen atom. Some inducing factors such 
as ET-1, angiotensin II, and TNFα (tumor necrosis factor 
α) are needed for such   activation. An increase in ROS in 
the vascular structure is accompanied with an elevation of 
inflammatory factors and cytokines, such as leptin and its 
receptor OBRB (obese receptor type b), and ET-1.10 Indeed, 
antioxidants reverse these changes, at least in part, of the com-
promised vascular relaxation. An increase in ROS promotes 
PKCε to be   phosphorylated, and H2O2 is actively implicated 
in   upregulating PKCε, and the reaction is substantially 
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Figure 1 The chemical structure of berberine (A) CPU86017 (p-benzyl-tetra-hydro-berberine) containing the two chiral centers (B) and CPU0213 a dual endothelin 
receptor antagonist (C).Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
789
eTA and NOX in vascular abnormality
  suppressed by either antioxidant tocopherol (vitamin E) or 
endothelin receptor antagonist CPU0213.18
Renal damage relating to microangiopathy is closely 
linked with hypertension and diabetes and is the consequence 
of vascular endothelial dysfunction. Evidence has been 
accumulated to indicate that oxidative stress and inflamma-
tion mediate a decrease in the eGFR (estimated glomerular 
filtration rate) of the kidney, in which an increase in ET-1 is 
a dominant factor for such prediction.19 There is also a link of 
an early impairment of Alzheimer’s disease with an upregula-
tion of regulatory subunit p47phox and the catalytic subunit 
gp91phox in vulnerable brain regions, relevant to vascular 
endothelial dysfunction of the cerebro-artery in the brain.20
Diabetic vasculopathy
Diabetes mellitus causes abnormal vascular activity by pre-
senting insulin resistance and hyperglycemia, which increases 
AGEs revealed by an increase in HbA1c in the blood stream. 
AGEs seem to be an entity of free radicals to attack the large 
molecules by losing their biological activity stemming from 
the negatively charged. Elevated oxidative stress occurs 
predominantly in diabetic patients and in animal diabetic 
models due to hyperglycemia, as well as oxidative modifica-
tion of atherogenic lipoproteins.20,21 The generation of ROS 
is mainly derived from mitochondrial dysfunction, which 
increases electron leak from the mitochondrial respiratory 
chain (MRC), and an activation of NOX results. High levels 
of glucose and lipids impair the activities of MRC complex 
enzymes and activate NOX responsible for the generation 
of ROS.23 Increased NOX activity found in diabetic patients 
contributes to vascular dysfunction. In diabetes, ET-1 levels 
are elevated and upregulation of ETA and ETB occurs in the 
vasculature, along with a reduction in NO bioavailability.1,4 
Activated ET receptors can also be found in diabetic com-
plications such as cardiomyopathy and testopathy.24–26 NOX 
is stimulated mainly by ETA, with PKC actively involved.27 
The vasoconstrictive activity of ET-1 is mediated by the 
activity of NOX, and an activation of the L-type calcium 
channels by ET-1 causes an influx of calcium ions through 
activating NOX.28 An interaction of ET-1 with ROS is known 
as the ET–ROS pathway, which activates the ERK signaling 
pathway and AP-1 transcriptional factor.29 There is a positive 
feedback mechanism between them via an activation of ERK. 
ROS activate p38 kinase, which further promotes ROS gen-
eration, forming a positive feedback loop to sustain   ROS-p38 
kinase signaling, which may associate with a reduction in 
SIRT1 protein expression. Overexpression or activation of 
SIRT1, an NAD+ -dependent protein deacetylase, is sensitive 
to oxidative signals by drug interventions and significantly 
reduces the status of oxidative stress.30
There are multiple factors implicated in vascular abnor-
malities under diabetic conditions.31 The matrix in the   diabetic 
vascular wall is altered due to changes in MMP2 and MMP9 
expression resulting in an increase in   accumulated fibroid 
substances, which may participate in adversely affecting 
vascular activity.12,16 The intercellular gap junction   connexin 
proteins are important for maintaining normal   vascular tone 
through passing small molecules between cells, among 
which Cx40 (connexin 40) is active in the vascular wall and 
its downregulation results in a compromised   pulmonary 
  vascular dilatation.12 Drug intervention normalizes the 
abnormal Cx43, leading to a recovery of the cardiovascular 
  abnormalities.22 An activated PKCε participates in the   process 
of vascular endothelial dysfunction relating to oxidative 
stress, and hyperphosphorylation of PKCε appears to be 
involved in insults related to stress or diabetic lesion.32
Without sustained hyperglycemia, insulin resistance 
alone is always found in obese individuals associating with 
reduced vasodilating response to Ach. On the other hand, 
while blood glucose has been well controlled with a low 
HbA1c, however, the morbidity of the cardiovascular system 
may not be relieved, with mortality remaining high. Diabetic 
nephropathy as a microvascular complication may progress 
further. The pathological changes are rarely reversible, but 
progressive, even the inciting factor has been removed and 
reduction in functional renal mass leads to hypertrophy of 
the remaining renal glomeruli and tubules. The adaptations 
place a heavy burden on the functional renal units leading to 
glomerular sclerosis and interstitial fibrosis.33 Hyperfiltration 
of the vascular structure of glomeruli is a causal factor to 
damage the kidney, thus, the end stage of renal disease may 
occur while blood glucose levels have been well controlled. 
It indicates that suppression on the cellular insults by diabetic 
lesions is critical to relieve the progress in diabetic complica-
tions. Upregulated ET receptors are related to hyperfiltration 
and an application of ET receptor   blocking agents is effective 
in reducing the microalbuminuria.34 An early application of 
insulin to keep well controlled blood glucose at the early 
stage of diabetes is beneficial in attenuating the occurrence 
of diabetic vascular complications, even hyperglycemia that 
appears later; the incidence and severity of complications may 
be reduced due to a mechanism of ‘metabolic memory’.35
Peroxisome proliferator-activated receptor gamma 
(PPARγ), a nuclear receptor and transcription factor in the 
steroid superfamily, is actively implicated in the diabetic 
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are clinically effective in relieving type 2 diabetes. Beyond 
its   activity to increase the sensitivity to insulin, PPARγ 
plays critical roles in the vasculature, in particular on 
endothelium-dependent relaxation.36 Migraine is associated 
with a   specific vascular risk profile assessed as vascular 
dysfunction,   compared with normal control; in patients with 
migraine the systolic blood   pressure, diastolic blood   pressure, 
blood   glucose, and insulin are increased in   association with 
an   elevated ET-1 and an increased carotid artery intima 
  thickness, which   coincides with a reverse relation to flow-
mediated vasodilation.37 As an indicator for early vascular 
  abnormality in   diabetes, the carotid intima-media thickness 
(IMT) is   significantly greater in   diabetics without macroan-
giopathy compared with the normal control, and the increased 
IMT is significantly progressive over a 30-month follow-up 
period in diabetics but not in the controls.38
Hypertension and stress-induced 
vascular abnormalities
Vascular endothelium impaired in primary hypertension 
shows a reduction in NO and an increase in ROS contributing 
to sustained elevated blood pressure. Some antihypertensive 
agents possess potent blood pressure lowering effect; then, it 
is interesting to explore if the impaired vascular endothelium 
in hypertensive patients treated with antihypertensive agents 
could be back to the normal range. The status of vascular 
endothelium can be evaluated by an application of Ach and 
N(G)-monomethyl-L-arginine (L-NMMA) for   inducing the 
stimulated and basal NO release in the endothelium   separately. 
After long-term medication with either valsartan or amlodipine, 
the amplitude of a lowered blood pressure effect is the same 
while back to below 140/90 mmHg. The vasodilatory response 
caused by Ach was significantly increased with valsartan as 
assessment of the maximal percentage change in the forearm 
blood flow compared with placebo; however, amlodipine 
does not produce a   significant vasodilatation to Ach. On the 
other hand, the basal release of NO as tested by L-NMMA is 
significant in the two medicated groups. It indicates that NO 
bioavailability and the stimulated NO release from endothelium 
are varied in response to drug interventions. Both NO depen-
dent and independent pathways can be significantly preserved 
by valsartan; despite the same antihypertensive activity, amlo-
dipine shows a partial effect on NO bioactivity.39 Following one 
year treatment with either valsartan or amlodipine in a separate 
clinical test, the baseline blood pressure was similar and the 
magnitude of the decreases in blood pressure did not differ 
during the   medication between groups.   Endothelial function, 
assessed by flow-mediated vasodilation, was   significantly 
improved with valsartan but not in those treated with amlo-
dipine. The   markers for oxidative stress, urinary excretion of 
8-  isoprostane and 8-hydroxy-2’-deoxyguanosine, were signifi-
cantly reduced with valsartan against amlodipine.40 In another 
trial hypertensive patients resistant to amlodipine and cande-
sartan were included, and either spironolactone or chlorthali-
done was added to improve the antihypertensive activity for 
16 weeks. The flow mediated vasodilation test was conducted 
while both medications caused significant reduction in blood 
pressure within the normal range and resulted in a decrease in 
vasodilation seen with chlorthalidone, but not spironolactone. 
An impaired vasodilative response is likely to be linked with an 
increase in inflammatory factors. C-reactive protein and uric 
acid in serum were increased significantly in patients treated 
with chlorthalidone compared with spironolactone.41 Some bio-
markers are related to impaired endothelial function in hyper-
tensive patients, a reduction in prostacyclin production, and an 
increased oxidized LDL associate with a 4.9 higher significant 
risk of hypertension.42 In primary hypertension NOX-derived 
superoxide, stimulated by AT1 receptors, decreases vascular 
endothelium released NO due to forming peroxynitrite by 
reacting with NO. Telmisartan decreases in the aortic levels of 
the protein expression of gp91, a subunit of NADPH oxidase, 
resulting in a relief to endothelial dysfunction.43 A blockade 
on the renin-angiotensin-aldosterone system is more beneficial 
than diuretics in relieving the endothelial dysfunction account-
ing for an increase in the vasodilating activity.
ETA receptor is activated in the resistance   vessels in 
patients with hypertension. Following an intra-  arterial   injection 
of ETA blocker BQ-123 in patients with   hypertension, the 
forearm blood flow is increased   significantly, and the vaso-
dilator response caused by BQ-123 in hypertensive subjects, 
but not in hypercholesterolemic patients or   smokers, was 
significantly greater relative to healthy individuals. Thus, 
vascular resistance of the peripheral artery is modulated 
selectively by ETA in hypertension.44
Chronic medication of isoproterenol mimicking a stress 
status related to an increase in sympathetic outflow, causes an 
impairment of vascular activity which is effectively reversed 
by endothelin receptor antagonist CPU0213.45 The abnormal 
vascular activity is characterized by an increase in expres-
sion of ETA, NOX, and MMP9 in the vasculature which are 
attenuated by either CPU0213 a blockade on ET receptors 
and an antioxidant activity by aminoguanidine.
The tone of the coronary arteries is critically dependent 
on an activation of ET receptors and an increased ET-1 
associates with a proportional decrease in NO accompanying 
coronary endothelial dysfunction.46 Vascular abnormalities Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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resulting from over-expression of endothelin receptor, leptin, 
and NOX and stress contribute to an increased risk of CVD   
(cardiovascular disease).
Endothelium-dependent dilatation of large arteries decr-
eases with aging even in the healthy elderly, and the flow-
mediated dilatation (FMD) further declines in hypertensive 
elderly patients, and measurement of carotid artery IMT 
provides a possible indicator of endothelial dysfunction. In 
the whole population, maximal Ach-induced vasodilation was 
inversely related to IMT, and the age-related impairment of 
endothelium-dependent vasodilation and remodeling of the 
carotid intima can be attenuated in individuals with regular 
physical training.47 An impairment of vasodilative response 
of the brachial artery may precede changes in the carotid IMT 
and left ventricular mass index with aging.48
Hyperlipidemia and obesity induced 
vascular abnormality
Blood cholesterol lowering drugs reduce the incidence 
of coronary heart disease, encouraging impetus to global 
campaigns to search for effective agents in reducing serum 
cholesterol levels. The plaques found in the arterial walls 
of patients with hypercholesterolemia indicate an important 
clue of linking their development with serum cholesterol. 
The involvement of ET-1 in the process of formation of the 
plaques in the vasculature has been established in association 
with a compromised vasodilatation.
Obesity is associated with increased cardiovascular risk 
due to vascular endothelial dysfunction, mean brachial artery 
FMD was impaired in obese individuals, and an improvement 
is significant following sustained weight loss, in association 
with reducing total and low-density lipoprotein cholesterol, 
glucose, HbA1c, and C-reactive protein.49 It indicates that 
chronic inflammatory reaction appears to be implicated in 
the endothelium dysfunction in obese individuals.
More attention has been paid on the early sign of intima 
damage, as a subclinical atherosclerosis, which   accompanies 
a reduction in the vascular activity. Evidence for existence 
of early changes relating to atherosclerosis in arterial intima 
is found as early as in the fetal period. The risk factors of 
pre-clinical atherosclerosis in childhood are presented as 
carotid artery IMT by high resolution B-mode   ultrasound. 
The   diastolic blood pressure and the pre-clinical   atherosclerosis 
appear to be the risk factors inducing the thickened carotid 
artery IMT.50 The distribution of IMT of the common carotid 
is not specific to hyperlipidemia, and some hyperlipidemia 
patients have abnormal IMT of the carotid, whereas in   others 
the femoral artery is more affected. Therefore, in patients 
with hyperlipidemia, such as familial hypercholesterolemia, 
a combined assessment of the carotid and femoral arterial 
walls may be a more accurate way to reveal the early arterial 
lesion relevant to total atherosclerotic burden.51
Primarily, therapeutic agents for the prevention of athe-
rosclerosis are targeted in treating hyperlipidemia and high 
blood pressure; these are relatively easily measured risk 
  factors. This strategy, however, is of less than optimal   efficacy 
as rates of CVD remain high. Therefore, a biomarker as 
ET-1 has been intimately implicated in the progression of 
atherosclerosis.52
The compromised vasodilation of the vasculature in pati-
ents with hypercholesterolemia can be assessed by   measuring 
flow-dependent vasodilation.53 There are many factors result-
ing in the abnormalities, one of which is likely related to an 
increase in plasma levels of asymmetric   dimethylarginine 
(ADMA), which is an endogenous   inhibitor to NO   genesis 
in vascular endothelium.54 An impaired vasodilation assessed 
by flow-mediated vasodilation in essential hypertension is 
also related to an increased ADMA in plasma, in associa-
tion with an elevated C-reactive protein, which indicates an 
involvement of inflammatory reactions in the vascular wall.55 
Cerebral vascular activity is damaged by hyperhomocysteine-
mia and is reversed by overexpression of dimethylarginine 
dimethylaminohydrolase, which has ADMA-hydrolyzing 
activity.56 The earliest abnormality in the vascular disease 
represents endothelial dysfunction, which appears to be linked 
with subsequent atherosclerosis progression as well as in the 
settings of diabetes mellitus, insulin resistance, dyslipidemia, 
and hypertension. In elderly subjects, the flow-mediated dila-
tion is conducted by injecting Ach to show positively relating 
to levels of L-arginine, and L-arginine/ADMA ratio, but not 
ADMA in plasma in elderly.57 Although L-arginine can be 
converted into vascular NO to dilate vascular smooth muscle, 
however, an increase in L-arginine levels up to 20 times higher 
than normal does not affect vasodilative activity and so did 
with ADMA levels, it may indicate multifaceted factors impli-
cated in the impairment of vascular activity. The subclinical 
atherosclerosis, high prevalence in airflow limited patients, 
can be found with carotid IMT and focal atheromatous plaque 
as indicators of vascular abnormality, which is coincided with 
increased morbidity and mortality from CVD due to chronic 
  obstructive pulmonary disease.58
Peripheral arterial disease detected 
by ankle brachial index
The ankle brachial index (ABI), a ratio of blood pressure mea-
sured at ankle over the blood pressure in the brachial artery, is Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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a known approach for assessing lower-limb peripheral artery 
disease (PAD). It serves as a marker   predicting CVD events. 
ABI predicts patients at risk for an increase in mortality from 
all causes, including CVD: patients with ABI 0.9–1.1, 0.7–0.9, 
and ,0.7 had hazard ratios of 1.60, 2.07, and 3.08 for all-cause 
mortality and 1.89, 2.33, and 4.09 for cardiovascular mortality, 
respectively.59 Abnormal ABI is associated with an increase 
in prevalence and recurrence of stroke.60 The measurement 
of ABI amongst patients with ischemic stroke may identify 
high-risk patients for   planning adequate prevention therapies. 
A modified ABI may be sensitive to find the patients at risk 
for CVD at the primary medical office.61
After acute ischemic stroke (AIS) or transient ischemic 
attack (TIA), ABI can be used to detect PAD as a marker of 
generalized atherosclerosis. A high prevalence of AIS, as high 
as 81.6%, is related to a low ABI and 18.4% with TIA.62 A low 
ABI of #0.9 is more likely to be in the elderly or in patients 
with a history of PAD, hypertension, diabetes, or congestive 
heart failure. It is also of interest to evaluate mortality across 
ABI values and to assess the association with elevated ABI. 
It has been found that an association between elevated ABI 
and poor survival is similar to that of low ABI. PAD appears to 
be an independent risk factor for mortality among patients with 
elevated ABI.63 A low ABI indicates atherosclerosis and an 
increased risk of cardiovascular and cerebrovascular events, 
and aspirin was tested for reducing the risk of cerebrovascular 
events; however, the outcome was negative.64
The ET – NADPH oxidase pathway
The impaired vasodilative responses and the reduced NO 
bioavailability may be addressed by an excess of ET-1 result-
ing in upregulation of ETA in the vascular wall, which is a 
consequence to diabetes, hypercholesterolemia,   hypertension, 
and aging. A reduction of hyperglycemia, cholesterol-lowering 
activity, and antihypertensive effect by agents may lead to a 
relief to the dysfunctional endothelium; however, the protective 
effect of these procedures may not be completely responded, as 
revealed in the clinical observations that diabetic nephropathy 
is relatively refractory to therapy and progressive.65
Attention should be paid on the maladaptive changes 
in the vascular wall in which an activated ET-NOX-PKCε 
pathway is focused. Angiotensin II(AII), a causal factor to 
the dysfunction of vascular endothelium, adversely stimulates 
the activity of the cardiovascular system through producing 
overt oxidative stress resultant from the activation of NOX. In 
these effects an activated ET is likely to mediate the activity of 
the AII through NOX activation as AII-evoked expression of 
ET-1 in adventitial fibroblasts appears to be mediated, at least 
in part, by NOX.66 The mitochondrial ROS is   responsible to 
mediate the activity of ET-1 in the   cardiovascular system.67 
The vascular activity of AII is closely related to ET-1, coro-
nary vasoconstriction by α1 – adrenergic stimulation via the 
α-adrenergic-angiotensin-ET axis which requires NOX medi-
ated signaling in cardiac and vascular cells.68 On the cardiac 
sympathetic nerve endings, ETA and ETB are located, and 
these two receptors are active in modulating the release of 
norepinephrine.69 The downregulation of FKBP12.6 (FOK 
binding protein, calstabin 2) as a consequence of isopro-
terenol or H2O2 medication is dramatically relieved by an 
application of endothelin receptor antagonist CPU0213.18 
Upregulation of NOX by isoproterenol is significant and is 
separately modulated by ETA and ETB antagonist; however, 
the activity of ETA is predominant in this regard.70 Therefore, 
it can be recognized that there is a functional link between the 
activity of sympathetic nervous system, AII and ET-1, and the 
activity of NOX serves as an important tie in the pathologies 
relating to an unhealthy vascular system.
In conclusion, agents reducing hyperglycemia and 
hypercholesterolemia may not be sufficient in relieving the 
  endothelial insults. A reversal of the abnormal endothelial 
status can be achieved by cell protective effects through sup-
pressing the ET-NOX-PKCε pathway. Agents may relieve 
the endothelium dysfunction by suppressing this pathway. 
The progression of the peripheral artery disease and the 
  pathologies implicated in the vascular beds in diabetes, hyper-
cholesterolemia, stress, and aging should be targeted by drug 
interventions. Therefore, it is likely to reduce the morbidity of 
CVD and   mortality of all causes through normalizing vascular 
endothelium function. It is hopeful for reducing risk of cere-
brovascular and cardiovascular attack by applying ingredients 
isolated from TCM which suppress the ET-NOX-PKCε axis, 
and it would be worth doing more tests for the potential to 
relieve these abnormalities in this regard.
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